During the past decade, Sichuan Cancer Hospital & Institute conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 1 clinical trials were completed, i.e. on average, 2.6% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 1 clinical trials were completed. i.e. 3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sichuan Cancer Hospital & Institute" #1 sponsor was "Sichuan Cancer Hospital and Research Institute" with 14 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 2 trials sponsored, "Suzhou Suncadia Biopharmaceuticals Co., Ltd." with 2 trials sponsored and "BeiGene" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sichuan Cancer Hospital & Institute" #1 collaborator was "Hebei Medical University Fourth Hospital" with 2 trials as a collaborator, "Jiangyou People's Hospital" with 2 trials as a collaborator, "Peking University Cancer Hospital & Institute" with 2 trials as a collaborator, "Affiliated Cancer Hospital & Institute of Guangzhou Medical University" with 1 trials as a collaborator and "Affiliated Hospital of Southwest Medical University" with 1 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Sichuan Cancer Hospital & Institute" are "Esophageal Squamous Cell Carcinoma" (6 trials), "Breast Cancer" (3 trials), "NSCLC" (3 trials), "Hepatocellular Carcinoma" (2 trials) and "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Sichuan Cancer Hospital & Institute" in a lesser frequency.

Most popular intervention types in "Sichuan Cancer Hospital & Institute" are "Drug" (30 trials), "Radiation" (8 trials), "Combination Product" (3 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (6 trials), "Placebo" (6 trials), "Cisplatin" (4 trials), "Carboplatin" (3 trials) and "Chemotherapy" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sichuan Cancer Hospital & Institute" are 38 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are 24 active trials in "Sichuan Cancer Hospital & Institute". 3 are not yet recruiting, 14 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 4 completed trials in Sichuan Cancer Hospital & Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Sichuan Cancer Hospital & Institute, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".